Pharmaceuticals
-
CanaQuest Bolsters Team for CQ-001 Trials
CanaQuest Medical (OTC: CANQF) adds experts to advance CQ-001 through clinical trials for FDA approval in epilepsy.
-
Sign-Ups For Novo Nordisk's Weight Loss Drug Soar In US
Novo Nordisk's weight loss drug Wegovy experiences booming sign-ups in the US, while facing pricing pressures and emerging competition.
-
Biogen Tops Q1 Estimates with Alzheimer's Boost
Dive into Biogen's impressive Q1 earnings, featuring an EPS beat and significant LEQEMBI sales growth. Explore what these results mean for the...
-
Johnson & Johnson (JNJ) Acquires Shockwave Medical (SWAV) for $13.1B
J&J acquires Shockwave Medical for $13.1B, bolstering its medical device portfolio and positioning retail investors for potential growth in the...
-
MDGL Stock Soars on FDA Liver Disease Approval
FDA approves first-ever NASH treatment, Rezdiffra, by Madrigal Pharmaceuticals Inc (NASDAQ: MDGL). Breakthrough for millions suffering from liver...
-
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research...
-
Eli Lilly's Zepbound Shows Short-Lived Weight Loss Benefits
Uncover key investment insights in the dynamic obesity drug market. Discover growth, value, and momentum strategies in this evolving healthcare...
-
AbbVie Stock in Focus with Strategic Cerevel Acquisition
AbbVie (ABBV) acquires Cerevel, enhancing its drug portfolio and opening new growth avenues in neuroscience for investors in ABBV stock.
-
BAYRY Stock: Bayer Faces Major Legal and Drug Dev Setbacks
Bayer's legal and pharmaceutical setbacks are something investors should pay attention to. These issues could impact BAYRY stock value and guide...
-
Investors Watch as Novo Nordisk Pours Billions into Obesity Drugs
Novo Nordisk invests $2.3 billion in France to expand its weight-loss drug production, marking a significant move in the pharmaceutical industry.
-
FDA Approves Eli Lilly's Weight Loss Drug Zepbound
Eli Lilly's Tirzepatide drug, already approved for treating Type 2 diabetes as Mounjaro, has received FDA approval for weight management under the...
-
Gilead Sciences Marks Two Years of Robust Growth
Gilead Sciences reports robust Q3 growth, driven by oncology and HIV treatments, highlighting a solid pipeline and strategic expansion in global...
-
Exact Sciences Records Stellar Q3 2023 Results
Exact Sciences showcases robust Q3 results, marking a turning point with increased revenue, diversified streams, and an upward trajectory.
-
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Toronto, ON – November 1, 2023 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...
-
EXACT Sciences Gears Up for Earnings Reveal
EXACT Sciences eyes a pivotal moment with its upcoming Q3 earnings report. The firm excels in ESG ratings and revenue, but operational costs raise...
-
Labor Dispute Hits CVS and Walgreens
A worker walkout at CVS and Walgreens poses investment questions. Learn more about potential impacts on retail investors.
